BEVERLY HILLS, Calif., Aug. 31, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. (“Eaton Scientific” or the “Company”), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to provide this update detailing recent comments made by Dr. Hootan Melamed, whose family’s Beverly Hills, CA based Rox San Pharmacy is the original compounding Pharmacy for Tropine 3, a Novel indication of Homatropine in oral suspension. Dr. Melamed filed the Patent for the drug’s new indication for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.
“Over the last six years, the Rox San Pharmacy team has been compounding Tropine 3 for southern California doctors that prescribe the drug to their patients for the treatment of hot flashes. Based on our interactions with the doctors and patients, it is our belief that Tropine 3 users have had a generally very positive response to the drug with no pronounced negative side-effects,” stated Dr. Hootan Melamed. “It is obvious that women across America and around the world could benefit from open access to this new drug, so we are very excited to see Eaton Scientific making progress in executing its plan to seek FDA Approval and fully commercialize Tropine 3. We would like to see our experience with the positive effects of the oral suspension version of Homatropine that Eaton has named Tropine 3 in a FDA Clinical Trial and move towards having Tropine 3 available for all women suffering from the effects of hot flashes.”
Rox San Pharmacy has over 40 years of experience with a highly-qualified and educated team of pharmacists, technicians, and chemists to custom prepare high-quality compounded and manufactured medications using several unique delivery systems including, but not limited to, lozenges, nasal spray, cream, lotion, or transdermal gel. Rox San Pharmacy services are utilized by a variety of health care participants, including new drug developers, dermatologists, plastic surgeons, orthopedic surgeons, and pain care specialists.
The Company is currently in advanced stage discussions with Rox San Pharmacy to provide expanded and ongoing compounding support during the highly anticipated Tropine 3 FDA compliant clinical trials expected to begin in September.
About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.
Forward-Looking Statements/Disclaimer
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions’ actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Eaton Scientific Systems, Ltd.
